Visionary Holdings (Nasdaq: GV) Launches Stem Cell-Based Anti-Aging Product Line, Accelerating Expansion into Asia's Premium Regenerative Medicine Market

Rhea-AI Summary

Visionary Holdings (Nasdaq: GV) announced on Nov 10, 2025 the commercial launch of a medical-grade stem cell anti-aging product line via its Hong Kong subsidiary, targeting the Chinese mainland, Hong Kong and Singapore with later expansion planned to Southeast Asia and North America.

GV said it has integrated a global technology licensing agreement with Jiangsu Yike Regenerative Medicine into three core product packages: the flagship Life Rejuvenation Program (mesenchymal stem cells, NK cell therapy, AI diagnostics), a Precision Repair Package with DFPP blood purification, and a Premium Personalized Program including full-genome sequencing and annual customized management.

Planned commercialization steps include a joint-venture production/clinical base, cross-border sales and branded clinic partnerships to support localized manufacturing and market rollout.

Positive

• Signed global licensing agreement with Jiangsu Yike
• Initial market rollout across Chinese mainland, Hong Kong, Singapore
• Three-tier product suite including flagship Life Rejuvenation Program

Negative

• None.

Insights

Commercial Strategy Expert

GV moves from R&D to commercial rollout of premium stem‑cell anti‑aging services across Asia and beyond.

Visionary Holdings ("GV") has launched a medical‑grade stem cell anti‑aging product line and will operate from its Asia‑Pacific hub in Hong Kong following a global licensing agreement with Jiangsu Yike Regenerative Medicine Co., Ltd. The product set targets high‑end clients with three tiers: a flagship Life Rejuvenation Program combining mesenchymal stem cells, NK cell therapy and AI diagnostics; a Precision Repair Package with DFPP blood purification; and a Premium Personalized Program with genome sequencing and annual management. The company also announced plans for a joint venture production/clinical base and a cross‑border sales network covering mainland China, Hong Kong, Southeast Asia and later North America.

Dependencies and risks include successful local manufacturing, clinical validation at the JV base, and establishing branded clinic partnerships across jurisdictions. Revenue realization depends on converting a narrow, high‑margin clientele; rollout timing and clinic openings will materially affect near‑term cash flows. Concrete items to watch: execution of the joint venture production/clinical application base, signing of distribution agreements across the stated regions, and commercialization progress in the upcoming fiscal years.

Regulatory and Clinical Implementation Expert

Product launch bridges licensed technology to market but hinges on clinical validation and regulatory approvals across target markets.

GV integrates Yike’s regenerative technologies into therapies that include stem cell therapy, NK cell revitalization, AI assessment and nano‑delivery systems, then plans localized manufacturing and clinical application through a joint venture. The operational model pairs biologic therapies with diagnostics and personalized services, which typically require clinical validation and regulatory clearances before broad clinical use.

Key risks are regulatory clearance pathways in each jurisdiction, clinical validation of safety and efficacy within localized production, and partnership terms with medical/aesthetic institutions. Monitor completion of clinical validation at the planned production/clinical base, any announced regulatory milestones in Hong Kong, mainland China or Singapore, and the timing of branded clinic openings; these will determine whether revenue expectations for the upcoming fiscal years become actionable.

HONG KONG, Nov. 10, 2025 /PRNewswire/ -- Visionary Holdings Inc. ("GV" or the "Company"), a technology-driven multinational enterprise listed on Nasdaq (Nasdaq: GV), today announced that its wholly owned subsidiary, Visionary Health Technology Group Limited, has official launch of its medical-grade stem cell anti-aging product line, initially targeting the Chinese mainland and broader Asian markets.

This launch marks a major milestone following GV's entry into the stem cell and medical aesthetics sector earlier this year, as well as its strategic partnership and global technology licensing agreement with Jiangsu Yike Regenerative Medicine Co., Ltd. ("Yike"), advancing the Company's commercialization in regenerative medicine.

Core Product Lines and Innovative Value Model

GV's anti-aging product portfolio includes three major categories:

• Comprehensive Regenerative Package — the flagship Life Rejuvenation Program, combining mesenchymal stem cells, NK cell therapy, and AI-based diagnostics, designed for entrepreneurs and high-net-worth individuals.
• Precision Repair Package — integrating targeted stem cell therapy and DFPP blood purification for clients with specific degenerative or chronic conditions.
• Premium Personalized Program — including full-genome sequencing, dual-institution medical consultations, and annual customized health management for ultra-high-net-worth clients.

This product launch marks GV's next operational milestone following its global licensing agreement with Yike, transitioning from R&D collaboration to tangible market implementation. GV has integrated Yike's proprietary regenerative technologies into a full suite of personalized anti-aging and cellular rejuvenation solutions, covering stem cell therapy, NK cell revitalization, AI-based health assessment, and nano-delivery systems.

The new products will be operated through GV's Asia-Pacific headquarters in Hong Kong, initially launching across Hong Kong, Singapore, and the Chinese mainland to provide premium, customized health solutions for high-end clients.

GV plans to advance its commercialization strategy through the following initiatives:

• Establish a joint venture production and clinical application base to enable localized manufacturing and validation of stem cell products;
• Build a cross-border sales and distribution network covering mainland China, Hong Kong, and Southeast Asia, while expanding into Canada, the United States, and Mexico;
  
  Partner with premium medical and aesthetic institutions to jointly develop branded clinics and anti-aging experience center

Management Comments

Xiyong Hou, CEO of Visionary Holdings, commented:

"The official launch of GV's stem cell-based anti-aging products marks an important milestone in transforming our technological assets into tangible commercial value. Since entering into our strategic partnership and global licensing agreement with Yike, GV has successfully advanced from technology development to market-ready products.

As Asia continues to be the fastest-growing market for regenerative aesthetics, this launch not only opens new revenue streams for GV but also establishes a solid foundation for our leadership in longevity and cellular rejuvenation technologies. The Company expects this product line to serve as a new driver of profitability in upcoming fiscal years and to further strengthen GV's visibility and positioning in the global capital markets."

About Visionary Holdings Inc.

Visionary Holdings Inc. (Nasdaq: GV) is a technology-driven multinational enterprise focused on innovative education, AI applications, and high-tech healthcare solutions. Headquartered in Toronto, Canada, the Company operates through its subsidiaries across North America and Asia, driving technological advancement, cross-border innovation, and global health transformation.

About Yike Regenerative Medicine

Jiangsu Yike Regenerative Medicine (http://jsyk.club) is a high-tech enterprise specializing in regenerative medicine and precision anti-aging technologies. The company operates across multiple platforms, including genetic engineering, stem cell research, and immune cell applications. Yike co-established the Institute of Aging and Regenerative Medicine with Jinan University, and holds numerous international patents and software copyrights. It also maintains ISO9001 and cGMP certifications, underscoring its commitment to quality and compliance.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will", "expects", "anticipates", "future", "intends", "plans", "believes", "estimates", "target", "going forward", "outlook," "objective" and similar terms. Such statements are based upon management's current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and which are beyond GV's control, which may cause GV's actual results, performance or achievements (including the RMB/USD value of its anticipated benefit to GV as described herein) to differ materially and in an adverse manner from anticipated results contained or implied in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in GV's filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. GV does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.

Contacts:

Visionary Holdings Inc.
Investor Relations
Email: IR@visionary.holdings

View original content:https://www.prnewswire.com/news-releases/visionary-holdings-nasdaq-gv-launches-stem-cell-based-anti-aging-product-line-accelerating-expansion-into-asias-premium-regenerative-medicine-market-302610020.html

SOURCE Visionary Holdings

FAQ

What did Visionary Holdings (GV) announce on Nov 10, 2025 about stem cell products?

GV launched a medical-grade stem cell anti-aging product line and said it will commercialize technologies licensed from Jiangsu Yike.

Which markets will GV target first with its stem cell anti-aging line (Nasdaq: GV)?

GV plans initial launches in the Chinese mainland, Hong Kong, and Singapore, with later expansion into Southeast Asia, Canada, the US, and Mexico.

What therapies are included in GV's flagship Life Rejuvenation Program (GV)?

The Life Rejuvenation Program combines mesenchymal stem cells, NK cell therapy, and AI-based diagnostics.

Will Visionary Holdings (GV) manufacture the stem cell products locally in Asia?

GV plans to establish a joint-venture production and clinical application base for localized manufacturing and validation.

How does GV plan to sell its new anti-aging products (Nasdaq: GV)?

GV intends to build a cross-border sales and distribution network and partner with premium medical and aesthetic institutions to open branded clinics and experience centers.

Does the Nov 10, 2025 announcement include financial guidance or pricing for GV's new product line?

The announcement did not disclose pricing or specific revenue guidance, only that the company expects the line to be a future profitability driver.